Mitoxantrone and Deafness neurosensory - a phase IV clinical study of FDA data

Summary:

Deafness neurosensory is reported as a side effect among people who take Mitoxantrone (mitoxantrone hydrochloride), especially for people who are male, 60+ old, also take Zometa, and have Prostate cancer metastatic.

The phase IV clinical study analyzes which people have Deafness neurosensory when taking Mitoxantrone. It is created by eHealthMe based on reports of 8,117 people who have side effects when taking Mitoxantrone from the FDA, and is updated regularly.

What is Mitoxantrone?

Mitoxantrone has active ingredients of mitoxantrone hydrochloride. eHealthMe is studying from 8,125 Mitoxantrone users. Check the latest studies of Mitoxantrone.

What is Deafness neurosensory?

Deafness neurosensory is found to be associated with 521 drugs and 949 conditions by eHealthMe. Check the latest studies of Deafness neurosensory.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 27, 2026

8,117 people reported to have side effects when taking Mitoxantrone.
Among them, 16 people (0.2%) have Deafness neurosensory.

Could Mitoxantrone cause Deafness neurosensory?

Among these 16 people:

What is the gender of people who have Deafness neurosensory when taking Mitoxantrone? *

female: 6.25 %
male: 93.75 %

What is the age of people who have Deafness neurosensory when taking Mitoxantrone? *

What are other drugs people take besides Mitoxantrone? *

What are other side effects people have besides Deafness neurosensory? *

Lymph Follicular Hypertrophy (an increase in the size of the lymph node follicles): 15 people, 93.75%
Back Pain: 15 people, 93.75%
Bronchitis (inflammation of the mucous membrane in the bronchial tubes): 15 people, 93.75%
Stress And Anxiety: 15 people, 93.75%
Pleural Effusion (water on the lungs): 15 people, 93.75%
Cardiac Failure Congestive: 15 people, 93.75%
Pain: 15 people, 93.75%
Tooth Abscess (pus formation in tooth): 15 people, 93.75%
Osteonecrosis Of Jaw (death of bone of jaw): 15 people, 93.75%
Urinary Tract Infection: 15 people, 93.75%

What are the existing conditions these people have? *

Prostate Cancer Metastatic: 8 people, 50.00%
High Blood Pressure: 7 people, 43.75%
Abdominal Discomfort: 7 people, 43.75%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 1 person, 6.25%
Multiple Myeloma (cancer of the plasma cells): 1 person, 6.25%
Metastases To Bone (cancer spreads to bone): 1 person, 6.25%
Bone Lesion (bone with abnormalities. bone lesions can result from growth formations, infections, or injuries): 1 person, 6.25%
Acute Promyelocytic Leukaemia (cancer of the blood and bone marrow): 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Mitoxantrone and have Deafness neurosensory?

- Check whether Deafness neurosensory is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Mitoxantrone:

Mitoxantrone (8,125 reports)

Browse all side effects of Mitoxantrone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Deafness neurosensory:

Deafness neurosensory (521 drugs)

Browse all the conditions that are associated with Deafness neurosensory:

Deafness neurosensory (949 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on mitoxantrone hydrochloride (the active ingredients of Mitoxantrone) and Mitoxantrone (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.